Details for Patent: 10,961,240

Which drugs does patent 10,961,240 protect, and when does it expire?

Patent 10,961,240 protects TURALIO and is included in one NDA.

This patent has twelve patent family members in nine countries.

Summary for Patent: 10,961,240

Title:	Formulations of a compound modulating kinases
Abstract:	Provided are compositions comprising Compound I having the following structure: or a pharmaceutically acceptable salt thereof, and a solubilizing agent; methods of making the same; and methods of using the same.
Inventor(s):	Prabha N. Ibrahim, Hamid Rezaei, Gary Conard Visor, Tomoari Kamo, Hiroshi Yamakose
Assignee:	Daiichi Sankyo Co Ltd , Daiichi Sankyo Inc
Application Number:	US16/510,757
Patent Claim Types: see list of patent claims	Use; Composition; Device; Dosage form;

Drugs Protected by US Patent 10,961,240

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-002	Oct 14, 2022		RX	Yes	Yes	10,961,240					TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-001	Aug 2, 2019		DISCN	Yes	No	10,961,240					TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY

International Family Members for US Patent 10,961,240

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018307910
Brazil	112019028235
Canada	3070505
China	110944670
European Patent Office	3658189
Japan	2020528884